QoL and associated factors in CML patients receiving second-line nilotinib

Key clinical point: Patients with chronic myeloid leukemia (CML) on second-line nilotinib therapy had above-moderate quality of life (QoL) that was influenced by sex, age, education, duration of nilotinib, and existing comorbidities.

Major finding: Patients on second-line nilotinib had above-moderate global health status/QoL scores (mean, 67.70±16.80) and experienced considerable symptoms, particularly fatigue (mean, 28.28±23.74), pain (mean, 21.07±26.16), and insomnia (mean, 22.87±29.20), along with financial difficulties (mean, 52.34±32.15). Female sex (P = .017), age (P = .002), higher level of education (P = .007), duration of nilotinib usage (P = .001), and number of comorbidities (P = .024) were significantly associated with global QoL.

Study details: This study assessed QoL using the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire in 121 adult patients with CML who were resistant or intolerant to imatinib and on second-line nilotinib for at least 3 months.

Disclosures: No funding was received for this study. The authors declared no conflicts of interest.

Source: Nguyen CTT et al. Qual Life Res. 2021 Jul 14. doi: 10.1007/s11136-021-02952-9.

Key clinical point: Patients with chronic myeloid leukemia (CML) on second-line nilotinib therapy had above-moderate quality of life (QoL) that was influenced by sex, age, education, duration of nilotinib, and existing comorbidities.

Major finding: Patients on second-line nilotinib had above-moderate global health status/QoL scores (mean, 67.70±16.80) and experienced considerable symptoms, particularly fatigue (mean, 28.28±23.74), pain (mean, 21.07±26.16), and insomnia (mean, 22.87±29.20), along with financial difficulties (mean, 52.34±32.15). Female sex (P = .017), age (P = .002), higher level of education (P = .007), duration of nilotinib usage (P = .001), and number of comorbidities (P = .024) were significantly associated with global QoL.

Study details: This study assessed QoL using the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire in 121 adult patients with CML who were resistant or intolerant to imatinib and on second-line nilotinib for at least 3 months.

Disclosures: No funding was received for this study. The authors declared no conflicts of interest.

Source: Nguyen CTT et al. Qual Life Res. 2021 Jul 14. doi: 10.1007/s11136-021-02952-9.

Key clinical point: Patients with chronic myeloid leukemia (CML) on second-line nilotinib therapy had above-moderate quality of life (QoL) that was influenced by sex, age, education, duration of nilotinib, and existing comorbidities.

Major finding: Patients on second-line nilotinib had above-moderate global health status/QoL scores (mean, 67.70±16.80) and experienced considerable symptoms, particularly fatigue (mean, 28.28±23.74), pain (mean, 21.07±26.16), and insomnia (mean, 22.87±29.20), along with financial difficulties (mean, 52.34±32.15). Female sex (P = .017), age (P = .002), higher level of education (P = .007), duration of nilotinib usage (P = .001), and number of comorbidities (P = .024) were significantly associated with global QoL.

Study details: This study assessed QoL using the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire in 121 adult patients with CML who were resistant or intolerant to imatinib and on second-line nilotinib for at least 3 months.

Disclosures: No funding was received for this study. The authors declared no conflicts of interest.

Source: Nguyen CTT et al. Qual Life Res. 2021 Jul 14. doi: 10.1007/s11136-021-02952-9.